Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Acromegaly
Related studies linked through entity extraction aliases.
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
- Status
- COMPLETED
- Phase
- PHASE4
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
- Status
- COMPLETED
- Phase
- PHASE3
Prediction of Tumor Shrinkage in Acromegaly
- Status
- COMPLETED
- Phase
- N/A
Cardiovascular Outcome After Surgery or Somatostatin Analogues
- Status
- COMPLETED
- Phase
- N/A
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
- Status
- COMPLETED
- Phase
- PHASE3
Acute Application of Pegvisomant and Octreotide in Acromegaly
- Status
- COMPLETED
- Phase
- PHASE4
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
- Status
- UNKNOWN
- Phase
- PHASE4
Ultrasound Guided Octreotide LAR Injection in Acromegaly
- Status
- COMPLETED
- Phase
- PHASE4
Physiopathology of Sodium Retention in Acromegaly
- Status
- COMPLETED
- Phase
- NA
Preoperative Octreotide Treatment of Acromegaly
- Status
- COMPLETED
- Phase
- PHASE4
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
- Status
- WITHDRAWN
- Phase
- PHASE2
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
- Status
- COMPLETED
- Phase
- N/A
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
- Status
- COMPLETED
- Phase
- PHASE3
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States
- Status
- COMPLETED
- Phase
- N/A
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
- Status
- RECRUITING
- Phase
- N/A
Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
- Status
- COMPLETED
- Phase
- PHASE4
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
- Status
- COMPLETED
- Phase
- PHASE1
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
- Status
- COMPLETED
- Phase
- PHASE3